In a notable move for the healthtech industry, HD, a healthtech company headquartered in Thailand, has secured a substantial investment from FEBE Ventures, a venture capital firm based out of Vietnam.
The new infusion of funds will bolster HD’s regional growth, especially in Vietnam where the firm foresees a vast market potential for its healthcare and surgery solutions. This comes on the heels of the firm’s successful fundraising efforts in January, where it amassed US$6 million from investors such as AC Ventures and M Venture Partners. Riding on this wave of funding, HD has set its sight on achieving profitability by the end of 2023.
Operating both outpatient and inpatient healthcare services through HDmall, HD has made its mark in Thailand and Indonesia by connecting patients with over 1,500 healthcare providers.
November 2022 witnessed the launch of HDcare, an innovative service offered by HD aimed at helping healthcare providers enhance their operating room utilization, while simultaneously ensuring patients can access surgeries more swiftly.
HD’s services have been met with an overwhelming response, evidenced by a 30x surge in patient demand since the rollout of HDcare. Founded in 2019, HD reports having assisted more than 250,000 patients with their healthcare needs so far.
In the aftermath of the Covid-19 pandemic, healthtech firms in the region are witnessing sustained support. For instance, last month saw Halodoc, an Indonesian startup, bagging US$100 million in a series D funding round, bringing its total funds raised to US$258 million.
This news story is based on an article from techinasia.com.
